ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Cancer Groups Criticize FDA For Ignoring Expert Advice.

November 24, 2000

NCAB working Group Is Not Subject To Open Meetings Law, NCI Official Says

December 9, 1994

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000

In Brief: Sullivan Will Be Secretary Most Knowledgeable About Cancer Program; Ihde Names ‘JNCI’ Editor

January 6, 1989

HHS Secretary Rebukes Task Force Guidelines On Breast Cancer Screening

November 29, 2009

Clinical Research Programs Could Be Accredited, IOM Says.

April 20, 2001